Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Something remarkable is happening in Chinese biotech, and it’s happening fast. The country’s drug developers are learning to ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...

On December 19, 2025, the National Security Commission on Emerging Biotechnology (NSCEB) announced the publication of a paper entitled “The Future of U.S.-China Biotechnology Competition.” The paper ...

The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...